Lung therapy device

Information

  • Patent Grant
  • 9050434
  • Patent Number
    9,050,434
  • Date Filed
    Thursday, May 15, 2008
    16 years ago
  • Date Issued
    Tuesday, June 9, 2015
    9 years ago
Abstract
The invention relates in general to a respiratory therapy device, and more specifically to an apparatus and method for providing continuous positive airway pressure therapy that may be connected to a small-volume nebulizer in order to provide a combination therapy that requires only a single source of gas. The apparatus of the invention includes a valveless patient interface and a source of pressurized gas which may be split into two streams to provide both continuous positive airway pressure therapy as well as aerosol therapy to a patient.
Description
FIELD OF THE INVENTION

The invention relates in general to a respiratory therapy device, and more specifically to an apparatus and method for providing continuous positive airway pressure therapy that may be connected to a small-volume nebulizer in order to provide a combination therapy that requires only a single source of gas.


BACKGROUND OF THE INVENTION

The health field is replete with devices intended to help resolve or prevent respiratory problems. Therapies that assist persons in taking deep breaths have been found to be beneficial in that this may expand airways. Among these therapies are continuous positive airway pressure therapy, and aerosol therapy.


Continuous positive airway pressure therapy, or “CPAP,” is often used for the treatment and prevention of atelectasis, which is the closing of part or the entire lung. Atelectasis is usually due to blockage in the airway and is exacerbated by very shallow breathing. CPAP is often used in hospitals on post surgical patients and patients who are confined to bed because they are particularly vulnerable to this condition. CPAP, which is also used to treat sleep apnea, delivers a positive pressure into the airways during both inhalation and exhalation in order to help open the airways and keep them open. It has been found to help in not only the reversal of atelectasis, but in its prevention as well. CPAP therapy may be delivered by connecting a single-patient CPAP device to a source of gas, such as a flow meter that regulates the flow of air or oxygen from a wall outlet. CPAP therapy is most often delivered to the patient through a mouthpiece or mask.


Another lung therapy that is commonly used to prevent or resolve atelectasis is aerosol therapy. This therapy is typically delivered by placing a liquid medication, such as a bronchodilator, into a small-volume nebulizer, connecting the nebulizer to a source of gas, most often regulated by a flow meter that regulates the flow of air or oxygen. The nebulizer converts the liquid medication into aerosol and, like CPAP therapy, is usually delivered to the patient through a mouthpiece or mask.


It has been found that the combination and concurrent delivery of CPAP and aerosol therapies is beneficial in that it reduces treatment time, and it is believed that each therapy enhances the effectiveness of the other. The aerosol delivery of a fast-acting bronchodilator may help to dilate airways allowing the CPAP pressure being introduced to have the maximum opportunity to be effective. Likewise, as the CPAP holds the airways open the aerosol has free access to the airways to do its job. This combination therapy may be administered by connecting a single-patient CPAP device to one source of gas controlled by a flow meter, connecting a nebulizer to the CPAP device, and connecting the nebulizer to another source of gas controlled by a flow meter.


Although this combination therapy is effective, potential problems may arise by having to connect each of the two therapy devices to separate gas sources. For example, there is often only one gas source available in a hospital room. In this case, a concurrent combination therapy would be precluded, or require the gathering of an additional portable gas source, such as a gas tank or portable compressor. If two gas sources are available in a room, an additional flow meter is required so that the nebulizer and the CPAP device can each be connected to its own gas source. Additionally, if there are two gas sources in a room, usually one is oxygen and the other air. This forces the clinician to connect one of the devices to air and the other to oxygen. In certain situations it may be advantageous to connect both the CPAP device and the nebulizer to the same type of gas. For example, in treating a patient in the end-stages of chronic obstructive pulmonary disease, it may be desirable to deliver the combination therapy using only air in order to avoid oxygen-flow induced retention of carbon dioxide. Similarly, when treating a patient with a condition that requires higher concentrations of oxygen it may be more beneficial to connect both the CPAP and the aerosol device to an oxygen source.


Thus, it would be desirable to have a single-patient, CPAP therapy device that can be connected to a nebulizer in order to deliver aerosol therapy under continuous positive pressure while requiring only a single gas source for the two devices or combination.


The present invention provides for such a combination therapy and connects to a single gas source.


SUMMARY OF THE INVENTION

The invention is a respiratory therapy device that provides continuous positive airway pressure and may be connected to a small-volume nebulizer to deliver a combination CPAP-aerosol therapy while connecting to a single gas source. It is comprised of a single-patient use continuous positive airway pressure therapy device, connectable to a small-volume nebulizer, a means for connecting both devices to a single gas source, and a means for restricting the flow of gas to at least one of the two devices.


Accordingly, an object of the present invention is to provide a means for delivering a CPAP-aerosol combination therapy even when only one gas source is available.


Another object of the present invention is to save time required in gathering additional gas sources and flow control devices in order to deliver a CPAP-aerosol combination therapy.


Another object of the present invention is to save the expense required securing additional gas sources and flow control devices in order to deliver a CPAP-aerosol combination therapy.


Another object of the present invention is to provide a means to connect both the CPAP device and the nebulizer to the same gas when only one air source and one oxygen source are available.





A BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a view of a preferred embodiment of the lung therapy device of present invention.



FIG. 2 is a rear view of a preferred embodiment of the lung therapy device of present invention.





DETAILED DESCRIPTION


FIG. 1 shows an embodiment of the present invention wherein a combination CPAP-aerosol therapy device 10 is formed by attaching a small-volume nebulizer 14 to a single-patient-use CPAP housing 12. Combination CPAP-aerosol therapy device 10 connects to a single gas source (not shown) with single-source gas connector 16.


To initiate the CPAP-aerosol therapy liquid medication is first placed into small-volume nebulizer 14, which is connected to CPAP housing 12 by press fitting nebulizer neck 38 into aerosol port 40. Single-source gas connector 16 is connected to a flow meter (not shown) to regulate the flow of an appropriate source of gas, typically air or oxygen. A manometer (not shown) may be connected to pressure monitoring port 34 in order to adjust the flow meter to achieve the desired pressure. Pressure monitoring port 34 is connected to the distal end of pressure monitoring conduit 42, which is fluidly connected to the proximal end chamber 55 of CPAP housing 12 in order to sense pressure proximal to the patient.


When the combination CPAP-aerosol device 10 has been readied for the therapy mouthpiece 56, which may also be a mask or some other appropriate patient interface, connects the patient to combination CPAP-aerosol device 10 and the patient is instructed to inhale from and exhale into the device.


Flow proceeds from single gas single-source gas connector 16 through singular tube 18 and is divided into two distinct flow streams as it enters Y connector 20. Y connector 20 connects to dual tubing 28, which consists of two tubes: nebulizer tube 58 and CPAP tube 60. From Y connector 20 one of the two flow stream enters into nebulizer tube 1st end 22, and the other flow stream enters CPAP tube 1st end 24.


The gas flowing through CPAP tube 60 continues until it exits CPAP tube 2nd end 32 and enters into the distal end chamber 36 (also referred to as entrainment cavity 36) of CPAP housing 12. Gas enters into distal end chamber 36 through gas inlet port 33 located in the circular end wall 64 of the distal end chamber 36. The gas flow travels through entrainment cavity 36 and is directed into venturi throat 44. In this embodiment CPAP device 12 contains a venturi 46 which serves as a flow amplification chamber. In alternate embodiments the venturi may be replaced by an amplification chamber which facilitates a Coanda effect, known within the medical industry, which similarly serves as a flow amplification chamber.


Gas flow continues through venturi 46 into proximal end chamber 55 and exits CPAP housing 12 through patient opening 54 and flows into the patient via mouthpiece 56. As the patient exhales, gas may exit exhalation port 62 which is made larger or smaller manipulating exhalation port selector ring 50. By observing manometer pressure exhalation port selector ring 50 may be used to achieve various CPAP pressures in conjunction with varying the flow of the single source gas with a flow meter. The manipulation of exhalation port selector ring 50 is achieved by adjusting exhalation port selector ring tab 52 so that it corresponds with one of three raised indicator dots 48. At one dot the exhalation port is open the most, thereby resulting in the lowest exhalation resistance. At dot three the exhalation port is open the least, thereby resulting in more resistance during exhalation. Accordingly, the housing may include a visual indicator and/or a tactile indicator for indicating the selected size of the exhalation port.


The gas flowing through nebulizer tube 58 is partially restricted by flow reduction orifice 26, which is calibrated in order to regulate the gas to a flow appropriate to drive nebulizer 14. Typically the appropriate flow ranges from 5 to 10 liters per minute. After the gas has passed through flow reduction orifice 26 it continues flowing through nebulizer tube 58 until exits nebulizer tube 2nd end 30, which is connected to nebulizer 14. The gas enters nebulizer 14 where it is utilized to convert the liquid medicine into aerosol. The aerosolized medication flows from nebulizer 14 through nebulizer neck 38 and is entrained into entrainment cavity 36 by way of aerosol port 40.



FIG. 2 depicts a rear view of Combination CPAP-aerosol therapy device 10 showing at least one entrainment opening 61 located in the circular end wall 64 of the distal end chamber 36 through which ambient gas enters into entrainment cavity 36 and mixes with aerosol from nebulizer 14. From there the gas-aerosol mixture enters venturi throat 44, where it travels through venturi 46 and finally out through mouthpiece 56.

Claims
  • 1. A lung therapy device for delivering continuous positive airway pressure, the lung therapy device comprising: a gas connector to receive a continuous positive flow of gas;a means for dividing said continuous positive flow of gas into two distinct continuous positive flow streams;a means for restricting the continuous positive flow of at least one of said two distinct continuous positive flow streams;a housing fluidly connected to at least one of said two distinct continuous positive flow streams and comprising a proximal end chamber located at a proximal end of said housing and a distal end chamber located at a distal end of said housing;said housing being devoid of valves that move during the therapy;said proximal end chamber having a patient opening which therethrough a patient may inhale inspiratory gas into said patient's airways and exhale expiratory gas from said patient's airways;said patient opening in said proximal end chamber further being fluidly connectable to a patient interface connector;said distal end chamber comprises: a substantially flat, substantially circular end wall which is substantially perpendicular to the axial dimension of the housing,a gas inlet port located in said substantially flat, substantially circular end wall and fluidly connectable to one of said two distinct continuous positive flow streams, anda plurality of entrainment ports open to ambient air, wherein the plurality of entrainment ports are located in said substantially flat, substantially circular end wall and arranged so that all ambient air entering the distal end chamber through the plurality of entrainment ports enters the distal end chamber substantially parallel with an axial dimension of the housing defined between the proximal end and the distal end of the housing;said housing further having a pressure monitoring port located at said distal end, said pressure monitoring port being substantially parallel with the axial dimension;said housing further containing an amplification chamber connecting said proximal end chamber to said distal end chamber which is shaped such that the flow of gas passing therethrough is amplified;said housing further containing a port connectable to a nebulizer; anda means for connecting said nebulizer to at least one of said two distinct continuous positive flow streams.
  • 2. The apparatus according to claim 1, wherein said proximal end chamber of said housing further includes at least one exhalation port open to the ambient.
  • 3. The apparatus according to claim 2, wherein said housing further contains a means for adjusting the size of said at least one exhalation port.
  • 4. The apparatus according to claim 3, wherein said means for adjusting said size of said at least one exhalation port is configured to divert the flow of exhaled gas away from a clinician.
  • 5. The apparatus according to claim 3, wherein said housing further comprises a visual indicator, wherein said visual indicator indicates the selected size of said at least one exhalation port.
  • 6. The apparatus according to claim 3, wherein said housing further comprises a tactile indicator, wherein said tactile indicator indicates the selected size of said at least one exhalation port.
  • 7. The apparatus according to claim 1, comprising a pressure monitoring conduit removably connected to said housing having a first end fluidly connected to said proximal end chamber of said housing, and a second end fluidly connected to one end of said pressure monitoring port.
  • 8. The apparatus according to claim 1, wherein said amplification chamber for amplifying said flow of gas within said housing is shaped to form a venturi.
  • 9. The apparatus according to claim 1, wherein said amplification chamber for amplifying said flow of gas within said housing is shaped to create a Coanda effect.
  • 10. A lung therapy device for delivering continuous positive airway pressure, the lung therapy device comprising: a gas connector to receive a continuous positive flow of gas;a means for dividing said continuous positive flow of gas into two distinct continuous positive flow streams;a means for restricting the continuous positive flow of at least one of said two distinct flow streams;a housing fluidly connected to at least one of said two distinct continuous positive flow streams and comprising a proximal end chamber located at a proximal end of said housing and a distal end chamber located at a distal end of said housing;said housing being devoid of valves that move during the therapy;said proximal end chamber having a patient opening which therethrough a patient may inhale inspiratory gas into said patient's airways and exhale expiratory gas from said patient's airways;said patient opening in said proximal end chamber further being fluidly connectable to a patient interface connector;said proximal end chamber of said housing further including at least one exhalation port open to the ambient air;said distal end chamber comprises: a substantially flat, substantially circular end wall which is substantially perpendicular to the axial dimension of the housing,a gas inlet port located in said substantially flat, substantially circular end wall and fluidly connectable to one of said two distinct continuous positive flow streams, anda plurality of entrainment ports open to the ambient, wherein the plurality of entrainment ports are located in said substantially flat, substantially circular end wall and arranged so that all ambient air entering the distal end chamber through the plurality of entrainment ports enters the distal end chamber substantially parallel with an axial dimension of the housing defined between the proximal end and the distal end of the housing;said housing further having a pressure monitoring port located at said distal end, said pressure monitoring port being substantially parallel with the axial dimension;said housing further containing an amplification chamber connecting said proximal end chamber to said distal end chamber which is shaped to form a venturi such that the flow of gas passing therethrough is amplified;said housing further containing a port connectable to a nebulizer;a means for connecting said nebulizer to at least one of said two distinct continuous positive flow streams.
  • 11. The apparatus according to claim 10, wherein said housing further contains a means for adjusting the size of said at least one exhalation port.
  • 12. The apparatus according to claim 11, wherein said means for adjusting said size of said at least one exhalation port is configured to divert the flow of exhaled gas away from a clinician.
  • 13. The apparatus according to claim 12, wherein said housing further comprises a visual indicator, wherein said visual indicator indicates the selected size of said at least one exhalation port.
  • 14. The apparatus according to claim 12, wherein said housing further comprises a tactile indicator, wherein said tactile indicator indicates the selected size of said at least one exhalation port.
  • 15. The apparatus according to claim 10, comprising a pressure monitoring conduit removably connected in said housing having a first end fluidly connected to said proximal end chamber of said housing, and a second end fluidly connected to one end of said pressure monitoring port.
  • 16. The apparatus according to claim 10, wherein said amplification chamber for amplifying said flow of gas within said housing is shaped to create a Coanda effect.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of priority from U.S. Provisional Application No. 60/938,865 filed on May 18, 2007.

US Referenced Citations (216)
Number Name Date Kind
402779 Steinhoff May 1889 A
1150238 Winbray Aug 1915 A
3068856 Bird et al. Dec 1962 A
3083707 Seeler Apr 1963 A
3291122 Engstrom et al. Dec 1966 A
3301255 Thompson Jan 1967 A
3537448 Liston Nov 1970 A
3561444 Boucher Feb 1971 A
3584621 Bird et al. Jun 1971 A
3630196 Bird et al. Dec 1971 A
3664337 Lindsey et al. May 1972 A
3861386 Harris et al. Jan 1975 A
4054134 Kritzer Oct 1977 A
4062358 Kritzer Dec 1977 A
4106504 York Aug 1978 A
4182599 Eyrick et al. Jan 1980 A
4195044 Miller Mar 1980 A
4245633 Erceg Jan 1981 A
4263907 Lindsey Apr 1981 A
4436090 Darling Mar 1984 A
4471773 Bunnell et al. Sep 1984 A
4558710 Eichler Dec 1985 A
4592349 Bird Jun 1986 A
4601465 Roy Jul 1986 A
4635857 Hughes Jan 1987 A
4747402 Reese et al. May 1988 A
4770164 Lach et al. Sep 1988 A
4805613 Bird Feb 1989 A
4823784 Bordoni et al. Apr 1989 A
4838260 Bird Jun 1989 A
4867151 Bird Sep 1989 A
4930501 Bird Jun 1990 A
4951659 Weiler et al. Aug 1990 A
4964404 Stone Oct 1990 A
4973047 Norell Nov 1990 A
4981295 Belman et al. Jan 1991 A
5007420 Bird Apr 1991 A
5018517 Liardet May 1991 A
5027809 Robinson Jul 1991 A
5067707 Kohnke Nov 1991 A
5069449 Wardwell Dec 1991 A
5107830 Younes Apr 1992 A
5116088 Bird May 1992 A
5127400 DeVries et al. Jul 1992 A
5150291 Cummings et al. Sep 1992 A
5165398 Bird Nov 1992 A
5193529 Labaere Mar 1993 A
5261394 Mulligan et al. Nov 1993 A
5277175 Riggs et al. Jan 1994 A
5322057 Raabe et al. Jun 1994 A
5355873 Del Bon et al. Oct 1994 A
5390665 Leach Feb 1995 A
5398676 Press et al. Mar 1995 A
5413110 Cummings et al. May 1995 A
5415161 Ryder May 1995 A
5423313 Olsson et al. Jun 1995 A
5439430 Rubens et al. Aug 1995 A
5451190 Liardet Sep 1995 A
5479920 Piper et al. Jan 1996 A
5535738 Estes et al. Jul 1996 A
5542416 Chalvignac Aug 1996 A
5547440 Rubens et al. Aug 1996 A
5570682 Johnson Nov 1996 A
5586551 Hilliard Dec 1996 A
5598839 Niles et al. Feb 1997 A
5617844 King Apr 1997 A
5617847 Howe Apr 1997 A
5664562 Bourdon Sep 1997 A
5666945 Davenport Sep 1997 A
5694919 Rubsamen et al. Dec 1997 A
5713349 Keaney Feb 1998 A
5823179 Grychowski et al. Oct 1998 A
5829429 Hughes Nov 1998 A
5862802 Bird Jan 1999 A
5906198 Flickinger May 1999 A
5937857 Caterini et al. Aug 1999 A
5938117 Ivri Aug 1999 A
5950619 Van Der Linden et al. Sep 1999 A
5964223 Baran Oct 1999 A
5970974 Van Der Linden et al. Oct 1999 A
6044841 Verdun et al. Apr 2000 A
6058932 Hughes May 2000 A
6076519 Johnson Jun 2000 A
6076520 Cooper Jun 2000 A
6079413 Baran Jun 2000 A
6085740 Ivri et al. Jul 2000 A
6085746 Fox Jul 2000 A
6116233 Denyer et al. Sep 2000 A
6167881 Hughes Jan 2001 B1
6210345 Van Brunt Apr 2001 B1
6234167 Cox et al. May 2001 B1
6240919 MacDonald et al. Jun 2001 B1
6269810 Brooker et al. Aug 2001 B1
6289892 Faithfull et al. Sep 2001 B1
6302105 Wickham et al. Oct 2001 B1
6336455 Howlett Jan 2002 B1
6340025 Van Brunt Jan 2002 B1
6355002 Faram et al. Mar 2002 B1
6363932 Forchione et al. Apr 2002 B1
6402046 Loser Jun 2002 B1
6405934 Hess et al. Jun 2002 B1
6412481 Bienvenu et al. Jul 2002 B1
6415791 Van Brunt Jul 2002 B1
6425393 Lurie et al. Jul 2002 B1
6427690 McCombs et al. Aug 2002 B1
6435175 Stenzler Aug 2002 B1
6450163 Blacker et al. Sep 2002 B1
6467476 Ivri et al. Oct 2002 B1
6526976 Baran Mar 2003 B1
6540153 Ivri Apr 2003 B1
6540154 Ivri et al. Apr 2003 B1
6546927 Litherland et al. Apr 2003 B2
6550472 Litherland et al. Apr 2003 B2
6550476 Ryder Apr 2003 B1
6557549 Schmidt et al. May 2003 B2
6568387 Davenport et al. May 2003 B2
6571790 Weinstein Jun 2003 B1
6581596 Truitt et al. Jun 2003 B1
6581598 Foran et al. Jun 2003 B1
6581600 Bird Jun 2003 B2
6588421 Diehl et al. Jul 2003 B1
6588422 Berthon-Jones et al. Jul 2003 B1
6595203 Bird Jul 2003 B1
6598602 Sjoholm Jul 2003 B1
6598603 Andersson et al. Jul 2003 B1
6609517 Estes et al. Aug 2003 B1
6612303 Grychowski et al. Sep 2003 B1
6615831 Tuitt et al. Sep 2003 B1
6626175 Jafari et al. Sep 2003 B2
6631721 Salter et al. Oct 2003 B1
6640806 Yurko Nov 2003 B2
6644304 Grychowski et al. Nov 2003 B2
6644310 Delache et al. Nov 2003 B1
6644311 Truitt et al. Nov 2003 B1
6663574 Faram et al. Dec 2003 B2
6679258 Strom Jan 2004 B1
6694969 Heinonen et al. Feb 2004 B1
6702998 Conner Mar 2004 B2
6708688 Rubin et al. Mar 2004 B1
6718969 Rubin et al. Apr 2004 B1
6722362 Hete et al. Apr 2004 B2
6729327 McFarland, Jr. May 2004 B2
6729334 Baran May 2004 B1
6737042 Rabinowitz et al. May 2004 B2
6752151 Hill Jun 2004 B2
6776159 Pelerossi et al. Aug 2004 B2
6805118 Brooker et al. Oct 2004 B2
6805120 Jeffrey et al. Oct 2004 B1
6823866 Jafari et al. Nov 2004 B2
6848443 Schmidt et al. Feb 2005 B2
6851426 Jaffre et al. Feb 2005 B1
6854462 Berthon-Jones et al. Feb 2005 B2
6880556 Uchiyama et al. Apr 2005 B2
6904906 Salter et al. Jun 2005 B2
6907881 Suki et al. Jun 2005 B2
6910479 Van Brunt Jun 2005 B1
6915803 Berthon-Jones et al. Jul 2005 B2
6932084 Estes et al. Aug 2005 B2
6948497 Zdrojkowski et al. Sep 2005 B2
6968840 Smith et al. Nov 2005 B2
7011091 Hill et al. Mar 2006 B2
7013894 McFarland, Jr. Mar 2006 B2
7036500 Niles et al. May 2006 B2
7059324 Pelerossi et al. Jun 2006 B2
7066176 Jaffe et al. Jun 2006 B2
7070761 Rabinowitz et al. Jul 2006 B2
7077133 Yagi et al. Jul 2006 B2
7100607 Zdrojkowski et al. Sep 2006 B2
7128069 Farrugia et al. Oct 2006 B2
7131439 Blacker et al. Nov 2006 B2
7165547 Truitt et al. Jan 2007 B2
7188621 DeVries et al. Mar 2007 B2
7191776 Niles et al. Mar 2007 B2
7191780 Faram Mar 2007 B2
7204245 Johnson et al. Apr 2007 B2
7210480 Lurie et al. May 2007 B2
7232417 Plante Jun 2007 B2
7302949 Pelerossi et al. Dec 2007 B2
7445607 Plante Nov 2008 B2
7469700 Baran Dec 2008 B2
7472702 Beck et al. Jan 2009 B2
7472705 Baran Jan 2009 B2
7500481 Delache et al. Mar 2009 B2
7562657 Blanch et al. Jul 2009 B2
7600511 Power et al. Oct 2009 B2
7699054 Pelerossi et al. Apr 2010 B2
20030051731 Be'eri et al. Mar 2003 A1
20030140921 Smith et al. Jul 2003 A1
20030140925 Sapienza et al. Jul 2003 A1
20030145849 Drinan et al. Aug 2003 A1
20030183226 Brand et al. Oct 2003 A1
20030205229 Crockford et al. Nov 2003 A1
20040003814 Banner et al. Jan 2004 A1
20050061318 Faram Mar 2005 A1
20050109340 Tehrani May 2005 A1
20050150489 Dunfield et al. Jul 2005 A1
20050165334 Lurie Jul 2005 A1
20050172954 Smith et al. Aug 2005 A1
20050217666 Fink et al. Oct 2005 A1
20060144398 Doshi et al. Jul 2006 A1
20060178245 Schiller et al. Aug 2006 A1
20060201500 Von Hollen et al. Sep 2006 A1
20060243274 Lieberman et al. Nov 2006 A1
20060272642 Chalvignac Dec 2006 A1
20070017522 Be-Eri et al. Jan 2007 A1
20070017523 Be-Eri et al. Jan 2007 A1
20070089740 Baumert et al. Apr 2007 A1
20070186928 Be'Eri Aug 2007 A1
20080000475 Hill Jan 2008 A1
20080000477 Huster et al. Jan 2008 A1
20080015456 McCawley et al. Jan 2008 A1
20080091117 Choncholas et al. Apr 2008 A1
20080190429 Tatarek Aug 2008 A1
20080264412 Meyer et al. Oct 2008 A1
20080283060 Bassin Nov 2008 A1
20090020121 Bassin Jan 2009 A1
Non-Patent Literature Citations (12)
Entry
A Manual on VDR-Volumetric Diffusive Repiration (VDR)—The VDR-4 Percussionator for the Most Challenging Patients Requiring Mechanical Cardiopulmonary Care—Percussionaire Corporation, Idaho, Copyright 1996 (75 pages).
Bird Demand CPAP, Bird Technical Information Manual, Copyright 1977 Bird Corp. (138 pages).
The Percussionaire Gold Edition IPV-1S(r) Universal Percussionator—Form 33120 Percusionaire Corporation, Idaho (2 pages).
The Basic Institutional Intrapulmonary Percussionator—Percussionaire Model IPV-1—Percussionaire Corporation, Idaho (2 pages).
The Bird—Instructor Reference Manual by Forrest M. Bird for the Bird Institute of Respiratory Technology,Apr. 1976 (14 pages).
Organization and Set Up of the Percussive VDR Intensive Care Breathing Circuit VDR Failsafe Breathing Circuit for Intensive Care—Percussionaire Corporation, Idaho (31 pages).
Intrapulmonary Percussive Ventilation IPV Discussion paper, Copyright Percussionaire 2000 (30 pages).
Specifications for Spanker Respirators, Copyright Percussionaire 1985 (6 pages).
Percussionaire Product Sheet, Dec. 12, 2002 (2 pages).
IPV-1C Institutional Intrapulmonary Percussionator spec., by Percussionaire Oct. 28, 2001 (2 pages).
IPV Users Manual, Copyright Percussionaire Dec. 1, 2000 (48 pages).
Letter dated Nov. 12, 2009 with enclosed Response dated Feb. 6, 2009 (80 pages).
Related Publications (1)
Number Date Country
20080283051 A1 Nov 2008 US
Provisional Applications (1)
Number Date Country
60938865 May 2007 US